RFG Advisory LLC Has $3.40 Million Stake in Amgen Inc. $AMGN

Key Points

• RFG Advisory LLC increased its stake in Amgen Inc. by 9.4% during the second quarter, bringing its total holdings to 12,176 shares valued at $3.4 million.
• Amgen reported a quarterly earnings per share (EPS) of $6.02, exceeding analyst expectations, with a revenue of $9.18 billion, a year-over-year increase of 9.4%.
• The company recently declared a quarterly dividend of $2.38 per share, representing an annualized yield of 3.2%.

RFG Advisory LLC increased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 9.4% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 12,176 shares of the medical research company's stock after purchasing an additional 1,047 shares during the period. RFG Advisory LLC's holdings in Amgen were worth $3,400,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. Nuveen LLC purchased a new stake in Amgen in the 1st quarter worth approximately $688,868,000. Federated Hermes Inc. lifted its position in Amgen by 48.5% in the 1st quarter. Federated Hermes Inc. now owns 2,037,169 shares of the medical research company's stock worth $634,680,000 after buying an additional 665,555 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Amgen by 128.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,065,694 shares of the medical research company's stock worth $332,017,000 after buying an additional 600,096 shares in the last quarter. WoodTrust Financial Corp lifted its position in Amgen by 8,223.6% in the 2nd quarter. WoodTrust Financial Corp now owns 595,634 shares of the medical research company's stock worth $166,307,000 after buying an additional 588,478 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in Amgen in the 2nd quarter worth approximately $156,812,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

Shares of AMGN opened at $293.85 on Wednesday. The company has a market capitalization of $158.20 billion, a PE ratio of 24.03, a price-to-earnings-growth ratio of 2.54 and a beta of 0.49. Amgen Inc. has a one year low of $253.30 and a one year high of $335.88. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The company's fifty day moving average price is $286.46 and its 200 day moving average price is $287.37.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping the consensus estimate of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business's quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were given a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.2%. The ex-dividend date was Friday, August 22nd. Amgen's dividend payout ratio (DPR) is currently 77.84%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on AMGN shares. Bank of America raised their price target on shares of Amgen from $261.00 to $272.00 and gave the company an "underperform" rating in a report on Friday, September 26th. Piper Sandler raised their price target on shares of Amgen from $328.00 to $342.00 and gave the company an "overweight" rating in a report on Monday, August 25th. Citigroup raised their price target on shares of Amgen from $310.00 to $315.00 and gave the company a "neutral" rating in a report on Wednesday, September 24th. Weiss Ratings upgraded shares of Amgen from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, October 8th. Finally, William Blair restated an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Eight research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Amgen currently has an average rating of "Hold" and an average price target of $309.42.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the firm's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.69% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.